Moderna said the FDA will determine the health-risk of vaccine.
The drug developer is the fifth company to have concluded discussions with the EU.
The company wants to take up the question of one or two doses in its first phase of trial.
The vaccine may be approved for use by humans within 3 to 7 days of registration by regulators.
Moderna has already begun experimental testing on humans.
The trials showed protective neutralization of antibodies and immune t-cells aimed at the virus.
The European Central Bank sees monetary stimulus in Europe to be necessary in the short term.
Goldman Sachs surged after it reported that its trading revenue doubled in the second quarter.
The human trials of the Oxford vaccine are expected to be through in September.
Participants received two doses of the potential vaccine.